FDA has approved dupilumab in patients of 12 years and older suffering from moderate-to-severe asthma. The study was conducted in three randomized, placebo-controlled, multicenter trials. Overall dupilumab was seen to improve lung function, reduced oral corticosteroid use, and reduced exacerbations regardless of baseline eosinophil levels. Currently, more than 4.3% of the population worldwide suffer from asthma.
Recently FDA has approved dupilumab after clinical trials suggested its efficacy in the treatment of 2 groups of uncontrolled asthma patient . The types of which were: patients with an eosinophilic phenotype or those with oral corticosteroid-dependent asthma . In the trial dupilumab was seen to exhibit its activity by inhibiting the hyperactivity of IL-4 and IL-13 , the two key proteins contributing to type 2 inflammation, underlying moderate-to-severe asthma . The drug was…
